# Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia

> **NCT00391560** · PHASE2 · COMPLETED · sponsor: **AEterna Zentaris** · enrollment: 19 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** perifosine

## Key facts

- **NCT ID:** NCT00391560
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-10
- **Final completion:** 2011-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391560, "Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00391560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*